{"classes":[{"categories":[{"measurements":[{"comment":"Seven out of 10 participants achieved a maximum response. Two participants who experienced DLTs were not evaluable for response and one participant who discontinued after two cycles of treatment did not achieve a response. Corresponding 95% confidence intervals is not calculable due to the low number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The time to maximum response to treatment will be assessed by determining the time required for each participant to achieve maximum response (defined above), and will be presented on Kaplan-Meier curves. The number of months taken to achieve this maximum response will be reported. Time to maximum response was analysed overall only, and not by arm due the small sample size.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set..","id":"OG000","title":"Safety Population"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Within 6 months","title":"Time to Maximum Response Based on Reported Data.","type":"SECONDARY","unitOfMeasure":"months"}